Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
- Conditions
- Advanced Solid Tumors With KRAS G12C MutationsSolid Tumor, AdultUnresectable Solid TumorMetastatic Solid TumorNon Small Cell Lung CancerColorectal CancerKRAS G12CPancreatic Cancer
- Interventions
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2025-09-16
- Lead Sponsor
- Frontier Medicines Corporation
- Target Recruit Count
- 403
- Registration Number
- NCT06244771
- Locations
- 🇺🇸
University of California San Diego (UC San Diego) Health - Jacobs Medical Center - Moores Cancer Center, La Jolla, California, United States
🇺🇸University of California Irvine (UCI) - Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
News
Frontier Medicines Unveils FMC-242, Novel PI3Kα/RAS Inhibitor Targeting Cancer's Most Common Genetic Drivers
Frontier Medicines announced FMC-242, a covalent allosteric inhibitor that breaks the PI3Kα/RAS protein interaction to target major cancer drivers without metabolic side effects.
Frontier Medicines Unveils DCAF2 as Novel E3 Ligase for Targeted Protein Degradation in Cancer Treatment
Frontier Medicines published groundbreaking research in Structure journal demonstrating that DCAF2 can be harnessed as a novel E3 ligase for targeted protein degradation.